Recruiting

Observational Study

Sponsor:

Yale University

Code:

NCT06725277

Conditions

Major Depression Disorder

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Spravato

IV Ketamine

Study Details

Brief summary:

This observational protocol is intended to provide long-term follow-up data on patients initiating or continuing treatment with either Spravato® or IV ketamine. This can provide us information on the patient acceptability and satisfaction, patterns of use, long-term effectiveness, and safety of the two approaches.

This 5-year, 6-site study will enroll 450 total patients. The sites will comprise 3 academic medical centers and 3 community psychiatric practices.

Conditions

Major Depression Disorder

Study ID

NCT06725277

Start date

Jan 21, 2024

Status verified date

Sep, 2026

Completion date

Dec, 2029

Anticipated

Primary completion date

Dec, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet the following criteria:

1. Recently started treatment (within 75 days of screening visit) with IV ketamine or Spravato® as prescribed by a clinician for the treatment of moderate to severe (based on an initial MADRS score ≥ 25) TRD (refractory to two or more antidepressant trials) without psychotic features and having appropriate baseline measures collected before starting treatment. These patients are referred to as treatment-continuing subjects.

OR
2. Scheduled to receive standard clinical treatment with IV ketamine or Spravato® as prescribed by a clinician for the treatment of moderate to severe (based on an initial MADRS score ≥ 25) TRD (refractory to two or more antidepressant trials) without psychotic features. These patients are referred to as treatment-initiating subjects.

In addition, in order to be eligible, an individual must meet all of the following additional criteria:
3. Adult ages 18 or older
4. Provision of signed and dated informed consent form prior to any study procedures
5. Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Diagnosis of bipolar disorder or psychotic disorder (i.e., schizophrenia, schizoaffective disorder)
2. Other psychiatric comorbidities are permitted so long as depression is the predominant diagnosis
3. Active or recent (within 12 months) substance use disorder (other than nicotine)

Study Design

Enrollment

450 participants

Anticipated

Interventions and Outcome Measures

Arms

IV Ketamine

Patients taking IV ketamine

Spravato

Patients taking Spravato, an intranasal form of ketamine

Interventions

Spravato

Intranasal esketamine

IV Ketamine

IV ketamine

Primary outcome measure

  • TSQM-9 [ Time Frame: baseline to 6 months ]

Central Contacts and Locations

Central contacts

Locations

Mood Institute

Recruiting

Milford, Connecticut, United States, 06461

Contacts

Principal Investigator:

Lisa Harding, MD

Yale School of Medicine

Recruiting

New Haven, Connecticut, United States, 06512

Emory University

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Brandon Kitay, MD, PhD

404-712-6939

Athena Care

Recruiting

Nashville, Tennessee, United States, 37228

Contacts

Principal Investigator:

Amanda Sparks-Bushnell, MD

Houston Center for Advanced Psychiatric Treatment

Recruiting

Bellaire, Texas, United States, 77401

Contacts

Principal Investigator:

Sandhya Prashad, MD

Seattle NTC

Recruiting

Seattle, Washington, United States, 98104

Contacts

Principal Investigator:

Rebecca Allen, MD

More Information

Sponsor

Yale University

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Yale University on 2026-09-03.